NervGen Pharma’s lead drug candidate, NVG-291, is being evaluated in an ongoing Phase Ib/IIa clinical trial in partnership with Shirley Ryan AbilityLab for patients with spinal cord injury (SCI). Unlike traditional approaches that manage symptoms, NVG-291 empowers the nervous system to repair itself. DDW’s Megan Thomas speaks with President and… Read More
Diana Spencer speaks to Dr Wansu Qiu, Technical Account Manager at Sino Biological US, about how advances in engineering technologies are paving the way for improved antibody drugs. DS: Since 1986, the FDA has granted marketing authorisation to over 100 therapeutic antibodies, many in oncology. Why has this been a… Read More
Suzanne Aitken, Senior Vice President of Managed Access at Clinigen, discusses the benefits of unlicensed medicines (ULMs) and why regulators and the industry need to do more to improve patient access to these therapies. The pharmaceutical industry is constantly changing. However, an unwavering problem is the constant unmet need… Read More
Mark Auty, lab automation and standardisation scientist at Unilever discusses why everyone has to be aware of cyber security threats. I’m not a cyber guy, I started working as a research chemist 25 years ago. Everyone had paper lab notebooks and only managers and a few instruments had computers. Windows… Read More
Antibody drug conjugates (ADCs) are among the hottest properties in pharma, powerful anticancer drugs that target tumours and deliver a lethal payload that destroys them, while leaving healthy tissues untouched. But there’s much more to come from this technology. DDW’s Megan Thomas explores the topic and speaks with experts… Read More
Cancer immunotherapy has set new standards in cancer care, but many patients are still not responding. RNA modifying enzymes (RME) research could be a way to improve results. DDW’s Megan Thomas reflects on STORM Therapeutics’ approach for the future of this mechanism of action. Turning points and catalysts… Read More
DDW’s Megan Thomas looks at a day in the life of Liam Tremble, Principal Scientist at Poolbeg Pharma. 1. Where do you work, and can you tell us what you’re working on at the moment? I work at Poolbeg Pharma, where we are developing novel treatments… Read More
Serna Bio was founded by Rabia Khan, who is also the CEO, to unlock the transcriptome as a drug discovery target. DDW’s Megan Thomas speaks to Khan about the work her team is doing to create the first map of the druggable transcriptome, which involves understanding RNA biology to discover… Read More
Imperial College spinout NK:IO was awarded a £1.6m ($2m) Innovate UK New Cancer Therapeutics grant in 2023 to develop a pioneering NK cell therapy. Diana Spencer catches up with Co-Founder Mike Romanos to find out more. DS: How can NK cell therapy tackle the limitations of cancer immunotherapy? MR: … Read More
On Friday 5 July, the United Kingdom saw a change in government to the Labour Party after 14 years of Conservative Party leadership. DDW’s Megan Thomas explores how this political change will influence the global life science sector. Economic power in the life sciences ecosystem According to… Read More
DDW’s Megan Thomas talks to Nicola McCarthy, Head of Research at the Milner Therapeutics Institute. MT: Could you start by giving me your name, your job title and what you do? NM: I’m Head of Research at the Milner Therapeutics Institute, which is part of the University of Cambridge, and… Read More
By DDW Editor Reece Armstrong The upcoming general election in the UK has placed the priorities of the country into the spotlight and the drug discovery sector should in no way be forgotten. Economic uncertainty, challenging global conditions and a healthcare system facing serious pressures, means that whatever government takes the… Read More
Following a trip to Copenhagen, Denmark, DDW’s Megan Thomas reflects on the Novo Nordisk Foundation’s efforts to tackle cardiometabolic diseases. According to presentations given at the Foundation’s HQ, more than 30% of the world’s population is overweight or obese and 537 million people live with… Read More
DDW’s Megan Thomas shines a spotlight on Rohan Thakur, President of Bruker Daltonics, as part of the first episode of the From the Top vodcast series. This interview took place while attending the opening of Bruker Corporation’s new production facility in Bremen. MT: What has you career path… Read More
The hormone GLP-1 (glucagon-like peptide-1) and its receptor agonists (GLP-1RAs) have emerged as a compelling class of drugs to tackle diabetes, particularly due to their remarkable efficacy in lowering obesity levels, a fundamental contributing factor of type 2 diabetes. But there is much more to come from this drug… Read More
Marc Hummersone, Senior Director of Research and Development (R&D) at Astrea Bioseparations, shares insight on the challenges and opportunities in cell and gene therapy (CGT) with DDW’s Megan Thomas. Lack of standardisation According to Hummersone, the major challenge in the CGT space is a lack of throughput that’s due to… Read More
